Cellectis Licenses TAL Technology from Iowa State | GenomeWeb

NEW YORK (GenomeWeb News) – Cellectis today announced two licensing agreements with Iowa State University granting the Paris-based genome engineering firm the rights to use inventions related to TAL effector-nucleases and monomeric TALENs.

The licenses allow Cellectis to use the technology in any field, it said. TALENs are sequence-specific DNA scissors that can be custom engineered to target and modify any gene of interest in any species.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.